Accelerating Toward Curing Myeloma: New Data, New Agents, and Evolving Treatment Paradigm

click the image above to view the replay

Join us for this live, CME-certified webinar featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma. You will have multiple opportunities to interact with faculty through interactive patient case scenarios and audience Q&A sessions.

View the Slides




Faculty Presenters

Brian G.M. Durie, MD
Shaji Kumar, MD
Thomas G. Martin, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesús F. San-Miguel, MD

Activity Launch Date – December 4, 2020

Activity Expiration Date – December 4, 2021

Goal Statement

The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory MM based on individual patient and disease characteristics
  • Explain the mechanism of action of newer classes of agents indicated for and under investigation for myeloma
  • Identify patients with relapsed/refractory MM who would be eligible for enrollment in late-phase clinical trials


Accreditation Statement

  • This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

Credit Designation

  • The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and mitigated according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

All staff at the Annenberg Center for Health Sciences at Eisenhower, Clinical Care Options and the International Myeloma Foundation involved in this activity have no relevant relationships to disclose.


Provided by the Annenberg Center for Health Sciences at Eisenhower and developed in partnership with Clinical Care Options, LLC and the International Myeloma Foundation.

Supported by educational grants from Amgen, Bristol Myers Squibb, Glaxo Smith Kline; Karyopharm Therapeutics, Inc; and Oncopeptides


IMF TV Blog Category

Source URL: